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This randomized, double-blind, parallel-group study compared the efficacy and tolerability of as-required 
salbutamol 100/~g administered from either a chlorofluorocarbon (CFC) pressurized metered ose inhaler (pMDI; 
Ventolin TM) or from a non-CFC hydrofluoroalkane.(HFA) 134a pMDI (VentolinTMCFC-free) in patients with 
mild to moderate asthma. All patients (n = 423) continued with their standard asthma therapy, and recorded their 
daily use of study medication, morning and evening peak expiratory flow (PEF) and symptom scores, throughout 
the 4-week treatment period. Clinic lung function was measured at 2-week intervals. 
The median daily use of inhaled study medication remained constant at four actuations per day throughout the 
study in both treatment groups and statistical analysis indicated that the two formulations were equivalent. Small 
improvements in both treatment groups were reported in mean morning and evening PEF, clinic forced expiratory 
volume in 1 sec and clinic PEF and there were no significant differences between the two groups. Both formulations 
were well tolerated. 
This study indicates that as-required salbutamol 1001~g administered via a HFA 134a pMD1 is as effective and 
safe as the currently available CFC-propelled formulation. 
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Introduction 
Salbutamol is probably the most commonly used respira- 
tory medication. Most asthma sufferers will have at least 
one salbutamol inhaler and the vast majority of these will 
be pressurized metered ose inhalers (pMDls). Because of 
the widespread use of this drug, reformulation of salbuta- 
tool pMDls with the approved replacement non-ozone 
depleting propellant, hydrofluoroalkane (HFA) 134a, has 
been a priority for the pharmaceutical industry (1). This is 
necessary to ensure continued availability of treatment 
during the transition away from the chlorofluorocarbon 
(CFC) propellants historically used in pMDI formulations. 
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The use of salbutamol on an as-required basis, often in 
addition to other inhaled and oral medications, has long 
been consistent with asthma treatment guidelines (2).The 
aim of this study was to compare the efficacy and safety of 
salbutamol 100/~g administered on an 'as-required' basis 
via a pressurized pMDI propelled by a mixture of 
propellants i l  and 12 (Ventolin TM) or by the non-CFC 
propellant HFA 134a (Ventolin TM CFC-free) in adult 
patients with mild to moderate asthma continuing with 
their standard asthma therapy. 
Methods 
PATIENTS 
Male or female patients aged >18 years were eligible for 
study entry if they had a documented history of mild to 
moderate asthma which responded to flz-agonist therapy and 
used a short-acting inhaled fl2-agonist for symptom control. 
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Patients were excluded if they had had changes in their 
regular asthma medication or a deterioration in dr 
exacerbation f their disease in the previous 4 weeks. Other 
exclusion criteria included treatment with a long-acting fl2- 
agonist in the previous 2 weeks, treatment with oral or 
parenteral corticosteroids on two or more occasions in the 
previous 4 months, asmoking history of > 20 pack years or 
a known hypersensitivity to fl2-agonists. Female patients 
who were pregnant, lactating or not taking adequate 
contraceptive precautions were also excluded. 
Patients were eligible for randomization to study treat- 
ment if at the end of a 2-week run-in period they were able 
to demonstrate a forced expiratory volume in 1 sec (FEVI) 
of greater than 50% but less than 100% of the predicted 
normal value and had taken an average of at least one 
actuation of salbutamol per day (but not more than 12 
actuations on any 2 days) in the last 7 days. 
All patients enrolled in the study provided written 
informed consent and ethics committee approval was 
obtained prior to commencement of he study. 
STUDY DESIGN 
This was a multi-centre, double-blind, randomized, paral- 
lel-group study conducted in 29 centres in Germany. The 
study comprised a 2-week run-in period, a 4-week treat- 
ment period and a 2-week follow-up period. 
On entry into the study, the patients' usual short-acting 
inhaled fl2-agonist herapy was discontinued and replaced 
with as-required,salbutamol 100pg administered from a 
pMDI containing the CFC propellants 11 and 12 for 2 
weeks. A spacer device was issued if required. Ongoing 
medications such as inhaled corticosteroids, odium cro- 
moglycate and oral methylxanthines were permitted uring 
the study provided the dose remained constant. Non- 
permitted medications, including fl2-agonists by any route 
and oral, parenteral or depot corticosteroids were discon- 
tinued at the beginning of the run-in period. 
At the end of the run-in period, if the eligibility criteria 
had been. met, patients were randomized to receive 
salbutamol 100#g as required for 4 weeks administered 
from a CFCsr  HFA 134a pMDI. 
EFFICACY MEASUREMENTS 
The following information was recorded aily by patients 
on diary cards during'the runin and treatment periods: the 
number of actuations of study treatment during the last 
24h; the highest of three morning and evening peak 
expiratory flow (PEF) measurements recorded using a 
mini-Wright peak flow meter; daytime symptoms on a six- 
point scale (0--no symptoms; 5 = symptoms so severe that 
the patient was unable to perform normal daily activities); 
and night-time symptoms on a five-point scale (0--no 
symptoms; 4=symptoms so severe that the patient was 
unable to sleep). 
Patients attended the clinic at 2-week intervals through- 
out the study. At each of these visits three measurements of 
FEVI and PEF were recorded, ideally with the patients 
having withheld their bronchodilator medication for 4h 
previously. 
SAFETY 
The investigator recorded any adverse vents at each clinic 
visit. Blood samples were collected at the start of the run-in 
period and after 4 weeks of treatment and sent to a central 
laboratory for haematological and biochemical nalysis. At 
the same time points, urinanalysis for blood, protein and 
glucose was performed using the dipstick method. Heart 
rate and blood pressure were measured at the beginning 
and end of the treatment period. 
STATISTICAL ANALYSIS 
Analysis was performed on the intent-to-treat (ITT) 
population, which comprised all randomized patients who 
received at least one dose of study medication. Hypothesis 
tests were used to assess clinical equivalence between the 
salbutamol CFC and HFA 134a pMDIs. No data were 
available to establish a suitable population sample size on 
the basis of the primary efficacy variable, median daily use 
of inhaled study medication. Thus, mean morning PEF, a 
commonly measured parameter, was used to determine 
sample size instead. Assuming a standard eviation of 30 to 
401min - l  as seen in previous studies, 125 evaluable 
patients per treatment group would ensure a power of 
80% (3). 
Median daily use of inhaled study medication was 
calculated from the diary cards and differences between 
the treatment groups were assessed using the Wilcoxon 
rank sum test stratified by centre using the van Elteren 
method (4). All diary card PEF variables, clinic FEVI, 
clinic PEF, systolic and diastolic blood pressure, heart rate 
and weight were analysed using analysis of covariance with 
baseline and age as covariates. 
The incidence of asthma exacerbations and study with- 
drawals were analysed using a chi-squared test and 90% 
confidence intervals (CI) were calculated. The use of study 
medication over 28 days and the daytime and night-time 
symptom scores were also analysed using a Wilcoxon rank 
sum test stratified by centre using the van Elteren method. 
For the incidence of adverse events, 90% CIs were 
calculated based on a binomial distribution. 
Resu l ts  
PATIENTS 
Of the 498 patients enrolled in the study, 423 were 
subsequently randomized to study medication: 215 patients 
received the salbutamol HFA 134a pMDI and 208 patients 
received the salbutamol CFC pMDI. Seventy-five patients 
were withdrawn from the study prior to randomization, 
mainly because of failure to meet he entry criteria 01 = 25) 
or adverse events (n=20). The treatment groups were 
well matched for age and history of smoking and asthma 
(Table I). 
MEDIAN DAILY  USE OF  LNHALED STUDY 
MEDICAT ION 
The median daily use of salbutamol in each treatment 
group was four actuations per day during the 2-week run-in 
period and this remained unchanged uring the treatment 
period (90% CI 0,0). 
Over the entire treatment period, the median daily use of 
study medication for individual patients ranged from 0 to 
15 actuations per day in the HFA 134a pMDI group and 
from 0 to 12 actuations per day in the CFC pMDI group. 
The frequency distribution of median daily medication use 
by individual patients in the two groups over weeks 1 to 4 
was similar, as shown in Fig. I (P=0.797). Treatment 
interactions with baseline, age, sex, centre, ethnic origin, 
spacer use, corticosteroid therapy and methylxanthine 
therapy were investigated but were not significant. The 
median use of study medication during the 4-week 
treatment period was 110 and 111 actuations in the HFA 
134a and CFC pMDI groups, respectively. 
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D IARY CARD LUNG FUNCTION 
In the HFA 134a pMDI group, the mean morning PEF 
increased from 366 I min-~ at the start of the treatment 
period to 375 1 min-1 by the end of week 4 (mean change 9 I 
min-  ~). In comparison, mean morning PEF increased from 
370 I min-  t to 373 1 rain- i in the CFC pMDI group. The 
adjusted mean change in morning PEF was 5 1 min-J  and 
41min - I  in the two groups, respectively, and the two 
groups were judged to be comparable (difference 1I min-  1 ; 
90% CI -4,6).  The adjusted changes in mean evening PEF 
in both groups over this time period were comparable 
(difference 1 I min - I  90% CI -4,5).  
The percentage predicted morning and evening PEF 
increased by 1% in both treatment groups from the end of 
the run-in period to the end of the 4-week treatment period 
(90% CI - 1,1). 
ASTHMA SYMPTOMS 
The median percentage of days with a symptom score < 2 
(i.e. no symptoms or symptoms for one short period only) 
was 86% in both groups at the end of the run-in period. 
TAnLE I. Patient characteristics 
Salbutamol HFA 134a pMDI Salbutamol CFC pMDI 
No. of patients: 215 
Age (years): 
Mean 48 
Range 19-79 
Sex (%): 
Males 51 
Females 49 
Ethnic Origin (%): 
Caucasian 98.5 
Black 0 
Oriental 1-5 
Duration of asthma (%): 
0-10 years 66 
11-20 years 22 
21-30 years 8 
>30 years : 3 
Spacer use (%) 10 
Smokers (%): 
Current 15 
Previous 33 
Non-smoker 53 
Asthma medication continued into study (%): 
Inhaled corticosteroids 61 
Methylxanthines 33 
Sodium cromoglycate 7 
Anti-cholinergics 3 
Nedocromil sodium 3 
208 
47 
18-80  
51 
49 
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63 
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1 
CFC, chlorofluorocarbon; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
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FIG.I. Frequency distribution of the median use of study medication during weeks 1-4. Salbutamol HFA 134a pMDI (I-'q); 
Salbutamol CFC pMDI (ll). 
This had increased to 100% in both groups by the end of 
the treatment period (90% CI 0,0). 
T.he median daytime symptom score at the start and end 
of treatment was l in both groups (i.e. symptoms for one 
short period during the day). The median night-time 
symptom score was 0 in the HFA 134a pMDI groups and 
l in the CFC pMDI group at the start of treatment. At the 
end of treatment the median score was 0 in both groups. 
EXACERBATIONS OF ASTHMA 
Nine patients (4%) in the HFA 134a pMDI groups had at 
least one exacerbation compared with 11 patients (5%) in 
the CFC pMDI groups (90% CI 0,0). 
CLINIC LUNG FUNCTION 
The adjusted mean change from baseline in clinic visit 
FEV~ at the end of the 4-week treatment period was 0.03 I 
in the HFA 134a pMDI group compared with 0.01 1 in the 
CFC pMDI (90% CI -0.05, 0.10). 
There were also small but similar increases in clinic PEF 
in both groups; the adjusted mean changes at the end of 
treatment were 31min -~ in the HFA 134a pMDI group 
and 41min -1 in the CFC pMDI group (difference 
-1  lmin -z 90% CI-11,10). 
ADVERSE EVENTS 
Overall, 56 patients (26%) in the HFA 134a pMDI group 
experienced an adverse vent during treatment compared 
with 39 patients (19%) in the CFC pMDI group. However, 
there was little difference in the incidence of individual 
adverse events between the two groups. The most 
commonly reported adverse vents were asthma (incidence 
of 3% in both groups), cough (3% in the HFA 134a pMDI 
group and 2% in the CFC pMDI group) and headache (2% 
in both groups). Predictable adverse vents were reported 
with a similar but very low incidence in both groups. 
The number of patients with adverse vents assessed by 
the investigator as drug-related was similar in both groups 
[13 patients (6%) in the HFA 134a and 12 patients (6%) in 
the CFC pMDI groups]. These events were predominantly 
ear, nose or throat disorders or miscellaneous disorders 
(e.g. malaise, pyrexia nd surgery); one patient in the HFA 
134a pMDI group reported an unpleasant taste. 
LABORATORY DATA 
Thirty-two patients (15%) in the HFA 134a pMDI group 
and 36 patients (18%) in the CFC pMDI group had 
changes in laboratory values which were considered to be of 
potential clinical significance. The most commonly reported 
changes were high potassium levels, thought o be due to 
haemolysed blood samples, and low lymphocyte counts, 
most of which occurred in patients with a low value at study 
entry. 
Discuss ion  
The objective of this study was to compare the as-required 
use of salbutamol 1001lg, propelled either by the CFC 
propellants I 1 and 12 (the currently marketed product) or 
by HFA 134a, a newly developed non-CFC propellant. The 
use of as-required salbutamol in this study reflects asthma 
treatment guidelines and is therefore relevant o clinical 
practice (2,5,6). 
The primary efficacy variable in this study, the median 
daily use of inhaled study medication, remained constant 
after treatment for 4 weeks with either formulation when 
compared with baseline. Exposure to the study medication 
was similar in both groups with a median use over the 4- 
week study period of 110 and 111 actuations in the HFA 
134a and CFC pMDI groups, respectively. This confirms 
that equivalence cannot be attributed to a lack of use of 
study medication. 
Secondary variables including mean morning PEF 
showed a slight improvement when compared with baseline 
at the end of the 4-week treatment period. The slight 
increase in mean morning PEF (observed in both groups) 
was unexpected in this study because patients remained on 
their usual concurrent asthma medication and only changed 
their rescue salbutamol medication. The change can 
perhaps be attributed to an increase in compliance which 
is often observed in a clinical trial setting. Statistical 
analysis of the data showed the two treatments to be 
comparable. Clinic visit lung function measurements also 
showed a small improvement in both treatment groups, 
with no difference observed between the groups. 
The tolerability profile of the two formulations in this 
study was similar. The total number of adverse events 
reported by patients in the HFA 134a pMDI group was 
slightly higher, but the incidence of individual events was 
similar between the groups. The incidence of predictable 
adverse events for inhaled fl2-agonists was low in both 
groups, with no reports of paradoxical bronchospasm, 
palpitations, muscles cramps or hypokalaemia during 
treatment. Laboratory analyses and vital signs also showed 
that there was no difference between the two treatment 
groups. 
The data in this study demonstrate that the reformula- 
tion has not affected the clinical efficacy and safety profile 
of salbutamol. These data are largely predictable given the 
similar h7 vitro particle size distribution of the HFA 134a 
and CFC pMDI formulations (7). Results from another 
study have shown that regular use of salbutamol at the 
maximum recommended dose of 200pg four times daily for 
3 months is equally well tolerated when administered from 
an HFA 134a or CFC pMDI (8). Similarly, salbutamol 
formulated with HFA 134a provided similar protection 
against histamine challenge in children and adults when 
compared with the currently available CFC-formulated 
product (1,9). Furthermore, the bronchodilator effect and 
tolerability profile of other salbutamol HFA formulations, 
with similar particle size distributions, have been shown to 
be comparable to the CFC-formulated product (10-12). 
In conclusion, this study indicates that salbutamol 
formulated with non-CFC propellant HFA 134a is as safe 
and effective as the currently available product which 
contains CFCs. 
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